DexCom Stock Based Compensation from 2010 to 2024

DXCM Stock

USD 72.83 1.63 2.19%

DexCom Stock Based Compensation yearly trend continues to be very stable with very little volatility. Stock Based Compensation is likely to drop to about 143.3 M. Stock Based Compensation is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. View All Fundamentals

Stock Based Compensation

First Reported

2005-03-31

Previous Quarter

44.7 M

Current Value

43.4 M

Quarterly Volatility

725 M

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check DexCom financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among DexCom's main balance sheet or income statement drivers, such as Interest Expense of 15.5 M, Other Operating Expenses of 3.2 B or Operating Income of 627.6 M, as well as many indicators such as Price To Sales Ratio of 23.64, Dividend Yield of 0.0 or PTB Ratio of 24.31. DexCom financial statements analysis is a perfect complement when working with DexCom Valuation or Volatility modules.

Check out the analysis of DexCom Correlation against competitors.

Latest DexCom's Stock Based Compensation Growth Pattern

Below is the plot of the Stock Based Compensation of DexCom Inc over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. DexCom's Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in DexCom's overall financial position and show how it may be relating to other accounts over time.

Stock Based Compensation

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Stock Based Compensation

Timeline

DexCom Stock Based Compensation Regression Statistics

	Arithmetic Mean	195,316,333
	Geometric Mean	89,580,287
	Coefficient Of Variation	209.46
	Mean Deviation	196,034,089
	Median	106,200,000
	Standard Deviation	409,113,752
	Sample Variance	167374.1T
	Range	1.7B
	R-Value	(0.34)
	Mean Square Error	159467.2T
	R-Squared	0.12
	Significance	0.22
	Slope	(31,062,364)
	Total Sum of Squares	2343236.9T

DexCom Stock Based Compensation History

	2024	143.3 M
	2023	150.8 M
	2022	126.5 M
	2021	113.4 M
	2020	119.4 M
	2019	102.7 M
	2018	101.9 M

Other Fundumenentals of DexCom Inc

Stock Based Compensation To Revenue

DexCom Stock Based Compensation component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Total Current Assets	Retained Earnings	Accounts Payable	Total Liab	Common Stock	Property Plant Equipment	Short Term Investments	Long Term Debt	Net Receivables	Short Term Debt	Current Deferred Revenue	Net Tangible Assets	Total Permanent Equity	Good Will	Capital Surpluse	Treasury Stock	Intangible Assets	Long Term Debt Total	Short Long Term Debt	Long Term Investments	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.98	0.95	1.0	0.81	0.92	0.99	0.81	0.98	0.98	0.97	0.97	0.38	0.76	1.0	0.81	0.84	0.88	-0.92	0.87	0.85	0.91	0.86	0.96	0.92	0.8
Total Stockholder Equity	0.98		0.89	0.98	0.73	0.88	0.96	0.72	0.94	0.97	0.93	0.92	0.42	0.65	0.99	0.8	0.87	0.92	-0.93	0.81	0.89	0.89	0.81	0.98	0.94	0.7
Net Debt	0.95	0.89		0.93	0.9	0.87	0.97	0.89	0.96	0.96	0.91	0.97	0.35	0.86	0.94	0.68	0.67	0.74	-0.83	0.89	0.7	0.79	0.81	0.88	0.81	0.89
Total Current Assets	1.0	0.98	0.93		0.76	0.93	0.99	0.77	0.95	0.98	0.98	0.96	0.34	0.73	0.99	0.83	0.86	0.9	-0.92	0.83	0.89	0.93	0.87	0.96	0.94	0.75
Retained Earnings	0.81	0.73	0.9	0.76		0.62	0.84	0.88	0.88	0.79	0.75	0.88	0.32	0.94	0.8	0.42	0.42	0.52	-0.69	0.87	0.44	0.54	0.65	0.74	0.62	0.92
Accounts Payable	0.92	0.88	0.87	0.93	0.62		0.92	0.74	0.88	0.9	0.92	0.9	0.34	0.68	0.89	0.9	0.87	0.86	-0.86	0.79	0.83	0.95	0.88	0.86	0.83	0.71
Total Liab	0.99	0.96	0.97	0.99	0.84	0.92		0.85	0.98	0.97	0.97	0.99	0.36	0.82	0.98	0.8	0.8	0.85	-0.91	0.89	0.82	0.9	0.88	0.94	0.89	0.84
Common Stock	0.81	0.72	0.89	0.77	0.88	0.74	0.85		0.89	0.76	0.75	0.91	0.45	0.91	0.78	0.57	0.54	0.56	-0.71	0.95	0.43	0.63	0.71	0.71	0.55	0.99
Property Plant Equipment	0.98	0.94	0.96	0.95	0.88	0.88	0.98	0.89		0.94	0.92	0.99	0.43	0.84	0.97	0.74	0.77	0.81	-0.9	0.93	0.74	0.82	0.82	0.92	0.83	0.88
Short Term Investments	0.98	0.97	0.96	0.98	0.79	0.9	0.97	0.76	0.94		0.95	0.94	0.35	0.71	0.98	0.76	0.8	0.87	-0.89	0.81	0.86	0.88	0.83	0.96	0.93	0.74
Long Term Debt	0.97	0.93	0.91	0.98	0.75	0.92	0.97	0.75	0.92	0.95		0.94	0.15	0.75	0.96	0.83	0.8	0.85	-0.87	0.76	0.86	0.93	0.9	0.91	0.93	0.73
Net Receivables	0.97	0.92	0.97	0.96	0.88	0.9	0.99	0.91	0.99	0.94	0.94		0.37	0.87	0.96	0.77	0.76	0.8	-0.87	0.92	0.73	0.85	0.86	0.9	0.82	0.9
Short Term Debt	0.38	0.42	0.35	0.34	0.32	0.34	0.36	0.45	0.43	0.35	0.15	0.37		0.24	0.37	0.26	0.43	0.39	-0.46	0.64	0.28	0.29	0.18	0.44	0.17	0.45
Current Deferred Revenue	0.76	0.65	0.86	0.73	0.94	0.68	0.82	0.91	0.84	0.71	0.75	0.87	0.24		0.74	0.52	0.42	0.47	-0.63	0.86	0.38	0.59	0.71	0.64	0.53	0.95
Net Tangible Assets	1.0	0.99	0.94	0.99	0.8	0.89	0.98	0.78	0.97	0.98	0.96	0.96	0.37	0.74		0.79	0.83	0.89	-0.92	0.84	0.86	0.88	0.84	0.97	0.93	0.77
Total Permanent Equity	0.81	0.8	0.68	0.83	0.42	0.9	0.8	0.57	0.74	0.76	0.83	0.77	0.26	0.52	0.79		0.9	0.84	-0.75	0.62	0.82	0.91	0.83	0.75	0.76	0.52
Good Will	0.84	0.87	0.67	0.86	0.42	0.87	0.8	0.54	0.77	0.8	0.8	0.76	0.43	0.42	0.83	0.9		0.97	-0.85	0.65	0.92	0.9	0.84	0.88	0.85	0.48
Capital Surpluse	0.88	0.92	0.74	0.9	0.52	0.86	0.85	0.56	0.81	0.87	0.85	0.8	0.39	0.47	0.89	0.84	0.97		-0.88	0.67	0.96	0.9	0.88	0.94	0.93	0.51
Treasury Stock	-0.92	-0.93	-0.83	-0.92	-0.69	-0.86	-0.91	-0.71	-0.9	-0.89	-0.87	-0.87	-0.46	-0.63	-0.92	-0.75	-0.85	-0.88		-0.81	-0.85	-0.87	-0.79	-0.93	-0.87	-0.68
Intangible Assets	0.87	0.81	0.89	0.83	0.87	0.79	0.89	0.95	0.93	0.81	0.76	0.92	0.64	0.86	0.84	0.62	0.65	0.67	-0.81		0.56	0.7	0.72	0.81	0.62	0.95
Long Term Debt Total	0.85	0.89	0.7	0.89	0.44	0.83	0.82	0.43	0.74	0.86	0.86	0.73	0.28	0.38	0.86	0.82	0.92	0.96	-0.85	0.56		0.92	0.82	0.91	0.95	0.4
Short Long Term Debt	0.91	0.89	0.79	0.93	0.54	0.95	0.9	0.63	0.82	0.88	0.93	0.85	0.29	0.59	0.88	0.91	0.9	0.9	-0.87	0.7	0.92		0.89	0.87	0.89	0.59
Long Term Investments	0.86	0.81	0.81	0.87	0.65	0.88	0.88	0.71	0.82	0.83	0.9	0.86	0.18	0.71	0.84	0.83	0.84	0.88	-0.79	0.72	0.82	0.89		0.85	0.84	0.69
Net Invested Capital	0.96	0.98	0.88	0.96	0.74	0.86	0.94	0.71	0.92	0.96	0.91	0.9	0.44	0.64	0.97	0.75	0.88	0.94	-0.93	0.81	0.91	0.87	0.85		0.95	0.69
Net Working Capital	0.92	0.94	0.81	0.94	0.62	0.83	0.89	0.55	0.83	0.93	0.93	0.82	0.17	0.53	0.93	0.76	0.85	0.93	-0.87	0.62	0.95	0.89	0.84	0.95		0.52
Capital Stock	0.8	0.7	0.89	0.75	0.92	0.71	0.84	0.99	0.88	0.74	0.73	0.9	0.45	0.95	0.77	0.52	0.48	0.51	-0.68	0.95	0.4	0.59	0.69	0.69	0.52

Click cells to compare fundamentals

About DexCom Financial Statements

DexCom investors utilize fundamental indicators, such as Stock Based Compensation, to predict how DexCom Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

	Last Reported	Projected for Next Year
Stock Based Compensation	150.8 M	143.3 M
Stock Based Compensation To Revenue	0.04	0.04

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether DexCom Inc is a strong investment it is important to analyze DexCom's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact DexCom's future performance. For an informed investment choice regarding DexCom Stock, refer to the following important reports:

How To Invest In DexCom

Details

Is DexCom Stock a good investment?

Details

What is DexCom's Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out the analysis of DexCom Correlation against competitors.

You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.157

Earnings Share

1.65

Revenue Per Share

10.089

Quarterly Revenue Growth

0.02

Return On Assets

0.0606

The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

DexCom Stock Based Compensation from 2010 to 2024

Latest DexCom's Stock Based Compensation Growth Pattern

DexCom Stock Based Compensation Regression Statistics

DexCom Stock Based Compensation History

Other Fundumenentals of DexCom Inc

DexCom Stock Based Compensation component correlations

About DexCom Financial Statements

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY